![Brazilian Journal Of Oncology - Metastatic castration-resistant prostate cancer (mCRPC) treated with 225Ac-PSMA-617. Case report Brazilian Journal Of Oncology - Metastatic castration-resistant prostate cancer (mCRPC) treated with 225Ac-PSMA-617. Case report](https://cdn.publisher.gn1.link/brazilianjournalofoncology.com.br/imagens/aop_8-fig02a.jpg)
Brazilian Journal Of Oncology - Metastatic castration-resistant prostate cancer (mCRPC) treated with 225Ac-PSMA-617. Case report
![18F]-Labeled PARP-1 PET imaging of PSMA targeted alpha particle radiotherapy response | Scientific Reports 18F]-Labeled PARP-1 PET imaging of PSMA targeted alpha particle radiotherapy response | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-022-17460-0/MediaObjects/41598_2022_17460_Fig1_HTML.png)
18F]-Labeled PARP-1 PET imaging of PSMA targeted alpha particle radiotherapy response | Scientific Reports
![225Actinium-labeled prostate-specific membrane antigen targeting peptide induces complete response in a metastatic prostate cancer patient - Omer Aras, Stefan Harmsen, Richard Ting, Haluk B Sayman, 2021 225Actinium-labeled prostate-specific membrane antigen targeting peptide induces complete response in a metastatic prostate cancer patient - Omer Aras, Stefan Harmsen, Richard Ting, Haluk B Sayman, 2021](https://journals.sagepub.com/cms/10.1177/20584601211022509/asset/images/large/10.1177_20584601211022509-fig1.jpeg)
225Actinium-labeled prostate-specific membrane antigen targeting peptide induces complete response in a metastatic prostate cancer patient - Omer Aras, Stefan Harmsen, Richard Ting, Haluk B Sayman, 2021
![Frontiers | Current role of prostate-specific membrane antigen-based imaging and radioligand therapy in castration-resistant prostate cancer Frontiers | Current role of prostate-specific membrane antigen-based imaging and radioligand therapy in castration-resistant prostate cancer](https://www.frontiersin.org/files/Articles/958180/fcell-10-958180-HTML/image_m/fcell-10-958180-g001.jpg)
Frontiers | Current role of prostate-specific membrane antigen-based imaging and radioligand therapy in castration-resistant prostate cancer
![Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine](https://jnm.snmjournals.org/content/jnumed/early/2023/08/23/jnumed.123.265546/F1.large.jpg)
Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine
![Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients](https://www.thno.org/v10/p9364/toc.jpg)
Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients
![Pharmaceutics | Free Full-Text | Development of [225Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC Pharmaceutics | Free Full-Text | Development of [225Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC](https://www.mdpi.com/pharmaceutics/pharmaceutics-13-00715/article_deploy/html/images/pharmaceutics-13-00715-g001.png)
Pharmaceutics | Free Full-Text | Development of [225Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC
![Pharmaceutics | Free Full-Text | Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis Pharmaceutics | Free Full-Text | Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis](https://www.mdpi.com/pharmaceutics/pharmaceutics-13-00722/article_deploy/html/images/pharmaceutics-13-00722-g002.png)
Pharmaceutics | Free Full-Text | Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis
![Structural formula of [ 225 Ac]Ac-PSMA-I&T, with DOTAGA as a chelator.... | Download Scientific Diagram Structural formula of [ 225 Ac]Ac-PSMA-I&T, with DOTAGA as a chelator.... | Download Scientific Diagram](https://www.researchgate.net/publication/351584466/figure/fig1/AS:1024889205047296@1621364036254/Structural-formula-of-225-AcAc-PSMA-I-T-with-DOTAGA-as-a-chelator-Structural.png)
Structural formula of [ 225 Ac]Ac-PSMA-I&T, with DOTAGA as a chelator.... | Download Scientific Diagram
![Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225 | EJNMMI Research | Full Text Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225 | EJNMMI Research | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13550-022-00935-6/MediaObjects/13550_2022_935_Fig3_HTML.png)
Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225 | EJNMMI Research | Full Text
![ProsTIC/PCF Global Webinar 2023: 225-Actinium-PSMA-617: Data and Perspectives from a Medical Oncologist ProsTIC/PCF Global Webinar 2023: 225-Actinium-PSMA-617: Data and Perspectives from a Medical Oncologist](https://www.urotoday.com/images/com-doc-importer/128-prostic-pcf-global-webinar-2023/prostic-pcf-global-webinar-2023-225-actinium-psma-617-data-and-perspectives-from-a-medical-oncologist/image-0.jpg)
ProsTIC/PCF Global Webinar 2023: 225-Actinium-PSMA-617: Data and Perspectives from a Medical Oncologist
![Development of Novel 111In/225Ac-Labeled Agent Targeting PSMA for Highly Efficient Cancer Radiotheranostics | Journal of Medicinal Chemistry Development of Novel 111In/225Ac-Labeled Agent Targeting PSMA for Highly Efficient Cancer Radiotheranostics | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.3c00346/asset/images/large/jm3c00346_0011.jpeg)
Development of Novel 111In/225Ac-Labeled Agent Targeting PSMA for Highly Efficient Cancer Radiotheranostics | Journal of Medicinal Chemistry
![225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine 225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine](https://jnm.snmjournals.org/content/jnumed/57/12/1941/F1.large.jpg)
225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine
Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA - European Urology
![⁶⁸Ga-PSMA-11 PET/CT scans of a representative patient with mCRPC after... | Download Scientific Diagram ⁶⁸Ga-PSMA-11 PET/CT scans of a representative patient with mCRPC after... | Download Scientific Diagram](https://www.researchgate.net/publication/337451979/figure/fig2/AS:941401936236555@1601459120845/Ga-PSMA-11-PET-CT-scans-of-a-representative-patient-with-mCRPC-after-1-cycle-of.png)
⁶⁸Ga-PSMA-11 PET/CT scans of a representative patient with mCRPC after... | Download Scientific Diagram
![Response to 225Ac-PSMA-I&T after failure of long-term 177Lu-PSMA RLT in mCRPC | European Journal of Nuclear Medicine and Molecular Imaging Response to 225Ac-PSMA-I&T after failure of long-term 177Lu-PSMA RLT in mCRPC | European Journal of Nuclear Medicine and Molecular Imaging](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs00259-020-05023-2/MediaObjects/259_2020_5023_Figa_HTML.png)
Response to 225Ac-PSMA-I&T after failure of long-term 177Lu-PSMA RLT in mCRPC | European Journal of Nuclear Medicine and Molecular Imaging
![Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine. | Semantic Scholar Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/ba3fdc2e8b913daf73b362c871bf9229937f4cfe/11-Figure10-1.png)